We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte Announces Data on Enzyme Inhibitor with Keytruda
Read MoreHide Full Article
Incyte Corporation (INCY - Free Report) and Merck & Co. (MRK - Free Report) announced an updated data from the advanced non-small cell lung cancer (NSCLC) patient cohort of the ongoing phase I/II ECHO-202 study. The study was evaluating Incyte’s selective IDO1 enzyme inhibitor epacadostat, in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab).
Epacadostat is being studied in combination with other immuno-oncology agents. In fact, Incyte signed clinical trial collaboration agreements with Merck, Bristol-Myers Company (BMY - Free Report) , AstraZeneca/MedImmune (AZN - Free Report) and Roche/Genentech to evaluate epacadostat with their respective anti-PD-1 and anti-PD-L1 agents in phase I/II studies in 2014. Currently, all four of these studies are in progress. Also, Incyte retains global development and commercialization rights to epacadostat for all indications.
In Oct 2015, Incyte and Merck announced an expansion of the companies’ ongoing clinical trial collaboration to include ECHO-301, a phase III study evaluating the combination of epacadostat with Keytruda as a first-line treatment for patients with advanced or metastatic melanoma.
In Mar 2017, Incyte and Merck announced details of the companies’ planned expansion of the ongoing clinical trial collaboration to include four additional tumor types, evaluating epacadostat plus Keytruda in patients with NSCLC, renal, bladder, and head & neck cancers. Phase III trials in these additional tumor types are expected to be initiated in 2017.
Incyte’s share price has increased 31.2% year to date, while the Zacks classified Medical - Biomedical and Genetics industry gained 2.8%.
Coming back to the release, the study showed an overall response rate (ORR) of 35% among all patients with advanced NSCLC treated with the combination of epacadostat and Keytruda. Notably, complete response was noted in two patients and partial response (PR) in 12 patients. It also demonstrated a disease control rate (DCR) of 63%, with 71% of responses ongoing at the time of the data cut-off.
Earlier, in Apr 2017, Incyte and Bristol-Myers Squibb announced that they will advance their clinical development program. The program will evaluate the combination of Incyte’s investigational oral selective IDO1 enzyme inhibitor epacadostat with Bristol-Myers’ immuno-oncology therapy Opdivo in phase III studies.
Moving ahead, the combination will be evaluated for the treatment of first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer.
Currently, Incyte and Bristol-Myers Squibb are expanding the ECHO-204 phase I/II study to include anti-PD-1/PD-L1 relapsed/refractory melanoma cohorts.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Incyte Announces Data on Enzyme Inhibitor with Keytruda
Incyte Corporation (INCY - Free Report) and Merck & Co. (MRK - Free Report) announced an updated data from the advanced non-small cell lung cancer (NSCLC) patient cohort of the ongoing phase I/II ECHO-202 study. The study was evaluating Incyte’s selective IDO1 enzyme inhibitor epacadostat, in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab).
Epacadostat is being studied in combination with other immuno-oncology agents. In fact, Incyte signed clinical trial collaboration agreements with Merck, Bristol-Myers Company (BMY - Free Report) , AstraZeneca/MedImmune (AZN - Free Report) and Roche/Genentech to evaluate epacadostat with their respective anti-PD-1 and anti-PD-L1 agents in phase I/II studies in 2014. Currently, all four of these studies are in progress. Also, Incyte retains global development and commercialization rights to epacadostat for all indications.
In Oct 2015, Incyte and Merck announced an expansion of the companies’ ongoing clinical trial collaboration to include ECHO-301, a phase III study evaluating the combination of epacadostat with Keytruda as a first-line treatment for patients with advanced or metastatic melanoma.
In Mar 2017, Incyte and Merck announced details of the companies’ planned expansion of the ongoing clinical trial collaboration to include four additional tumor types, evaluating epacadostat plus Keytruda in patients with NSCLC, renal, bladder, and head & neck cancers. Phase III trials in these additional tumor types are expected to be initiated in 2017.
Incyte’s share price has increased 31.2% year to date, while the Zacks classified Medical - Biomedical and Genetics industry gained 2.8%.
Coming back to the release, the study showed an overall response rate (ORR) of 35% among all patients with advanced NSCLC treated with the combination of epacadostat and Keytruda. Notably, complete response was noted in two patients and partial response (PR) in 12 patients. It also demonstrated a disease control rate (DCR) of 63%, with 71% of responses ongoing at the time of the data cut-off.
Earlier, in Apr 2017, Incyte and Bristol-Myers Squibb announced that they will advance their clinical development program. The program will evaluate the combination of Incyte’s investigational oral selective IDO1 enzyme inhibitor epacadostat with Bristol-Myers’ immuno-oncology therapy Opdivo in phase III studies.
Moving ahead, the combination will be evaluated for the treatment of first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer.
Currently, Incyte and Bristol-Myers Squibb are expanding the ECHO-204 phase I/II study to include anti-PD-1/PD-L1 relapsed/refractory melanoma cohorts.
Incyte Corporation Price
Incyte Corporation Price | Incyte Corporation Quote
Zacks Rank
Incyte carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>